NMUR1 (Neuromedin U Receptor 1)

Multivariate Cox analysis confirmed that the risk signature provided independent predictive information from clinical variables. In conclusion, the risk signature accurately identifies breast cancer patients at risk of lung metastasis, enabling clinicians to better assess risk and tailor treatment strategies effectively.

The drug sensitivity study showed that patients in the high-risk group had higher IC50 values for BMS-754807_2171 and Doramapimod_10424. Finally, in vitro experiments demonstrated that knocking down ANLN noticeably inhibited the viability, migration, and invasion of A549 cells. This study may provide a theoretical reference for future exploration of potential diagnostic and prognostic biomarkers for LUAD.

Additionally, NMUR1 suppression enhances CRC cell proliferation and invasiveness. Our integrated analyses and experiments open new avenues for personalized immunotherapy strategies in CRC treatment.

In vitro the presence of LDHA inhibitor can reduce the production of lactic acid stimulated by NMU, which can increase the anti-tumor activity of CD8 T cells. Moreover, treatment of the pancreatic cancer cells with a phosphoinositide 3-kinase (PI3K) inhibitor diminished NMU-induced lactate production and the activities of PK and LDH, suggesting that NMU might regulate glycolysis via the PI3K/AKT pathway.

We propose that NMU is involved in the modulation and promotion of the pro-metastatic tumour microenvironment in CRC through the activation of cancer cells and other tumour niche cells, macrophages and endothelial cells. Video abstract.

hsa_circ_0008234/hsa-miR-490-3p/SYT1 and hsa_circ_0002360/hsa-miR-1293/ (ADCY9, NMUR1) networks were established, and identified molecules may be involved in pathogenesis and prognosis in patients with LUAD.